http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Twist Bioscience to Present at Upcoming Investor Conferences
-
Twist Bioscience Launches Human Methylome Panel to Enable Detection of Methylation Fractions in a Diverse Range of Applications
-
Twist Bioscience to Present at the 2022 UBS Global Healthcare Conference
-
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience
-
Twist Bioscience Announces Participation in SRC Panel at the 2022 MRS Spring Meeting and Exhibit
-
Twist Bioscience Corporation (TWST) Enters License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression
-
Twist Bioscience Enters into Research, Exclusive Option and License Agreement with Astellas for Antibodies to Reduce Tumor Microenvironment-Mediated Immunosuppression
-
Twist Bioscience Reports Second Quarter 2022 Financial Results
-
Twist Bioscience Highlights Synthetic Libraries and High Throughput Antibody Discovery Platform at PEGS Boston 2022
-
Twist Bioscience Launches High Throughput Antibody Production Platform
-
Twist Bioscience Announces Promotions and Changes to Executive Leadership Team
-
Twist Bioscience to Report Fiscal 2022 Second Quarter Financial Results on Thursday, May 5, 2022
-
Twist Bioscience Corporation (TWST) Enters Collaboration with MediSix Therapeutics to Develop T-cell Therapies
-
Twist Bioscience Signs Antibody Discovery Collaboration with MediSix Therapeutics to Develop T-cell Therapies
-
DNA Data Storage Alliance Welcomes 50th Member
-
Twist Bioscience (TWST), Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy
-
Twist Bioscience and Kriya Sign Agreement to Discover Novel Antibodies for Applications in Oncology Using Gene Therapy
-
Twist Bioscience to Present at Upcoming Virtual Conferences
-
Twist Bioscience to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
-
Twist Bioscience Corporation (TWST) and Eleven Create Replicon for Development of Antiviral Tools
-
Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools
-
Twist Bioscience Reports First Quarter 2022 Financial Results
-
Twist Bioscience Corporation (TWST) and Abcam (ABCM) Collaborate on Antibody Discovery for Diagnostic and Research Applications
-
Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications
-
Twist Bioscience Releases Inaugural ESG Report Highlighting Achievements and Initiatives in Diversity and Sustainability
-
Twist Bioscience Corporation (TWST) Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics
-
Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics
-
Twist Bioscience to Report Fiscal 2022 First Quarter Financial Results on Friday, February 4, 2022
-
Twist Bioscience’s Comprehensive DNA Synthesis Capabilities Expanded as Industry-Leading Enzymatic Synthesis Process Unveiled at Annual J.P. Morgan Healthcare Conference
-
Twist Bioscience Creates Custom Whole Exome Target Enrichment Panel for Canine Genomic Research
-
Revelar Biotherapeutics and Twist Bioscience Announce RBT-0813 Neutralizes SARS-CoV-2 Omicron (B.1.1.529/BA.1) and Delta (B.1.617.2) Variants
-
Twist Bioscience to Present at the 40th Annual J.P. Morgan Healthcare Conference
-
Twist Bioscience Launches 96-Plex Library Prep Kit for Low Pass High Throughput Next-Generation Sequencing
-
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR Targets
-
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies Against GPCR Targets
-
Twist Bioscience Corporation (TWST) Now Shipping Synthetic RNA Positive Controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests
-
Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests
-
Twist Bioscience Announces Participation in SRC-SIA Webinar on the Decadal Plan for Semiconductors
-
Twist Bioscience to Present at Upcoming Virtual Conferences
-
Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results
-
Twist Bioscience Corporation (TWST) to Acquire Abveris
-
Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities
-
Twist Bioscience Expands Partnership with Invetx to Include Discovery of Best-in-Class Antibodies to Treat Multiple Diseases in Cats and Dogs
-
Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases
-
Twist Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference
-
Twist Bioscience Named in Inc.’s First Annual Best-Led Companies List
-
Twist Bioscience to Report Fiscal 2021 Fourth Quarter and Full Year Financial Results on Monday, November 22, 2021
-
Twist Bioscience Launches Exome 2.0 for Genomics Research
-
Twist Bioscience and the Broad Institute Create Custom Whole Exome Target Enrichment Panel for Clinical Research
-
Twist Bioscience Appoints Steffen Hellmold as Senior Vice President, Business Development, Data Storage
